Tenqual homeBrowse public tender search
SAM.gov

Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

Unknown purchaserUnited States

Purchaser

Country

United States

Notice published

5 Feb 2026

Tenqual indexed

7 Feb 2026

Closing date

2 Apr 2026

Source ID

Docs found

Create a free account to save this tender

Save this notice and create a tender alert for similar public opportunities.

Tender documents

5 files identified

Create a free account to open the 5 files linked to this notice.

Files identified
  • Create one free tender alert.
  • See a short explanation of why each tender matches.
  • Upgrade later when you want help planning and writing the bid.

Tender summary

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P& T COMMITTEE MEETING: The following MAY 2026 drug classes/subclasses will be reviewed: a. Antihemophilic Agents - Non-Factor Agents ALHEMO PEN HEMLIBRA HYMPAVZI PEN QFITLIA b. Leukemia and Lymphoma - BCR-ABL-TKI BOSULIF DANZITEN ICLUSIG IMKELDI PHYRAGO SCEMBLIX SPRYCEL TASIGNA NILOTNIB TARTRATE The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9201. Pre-quotation teleconference is on February 11, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Solicitation Number: HT9402-26-Q-9201 Type: Solicitation Base Type: Solicitation NAICS: 325412 Classification Code: 6505 Response Deadline: 2026-04-02T12:00:00-05:00 Office Address: JBSA FT SAM HOUSTON, TX Place of Performance: San Antonio, Texas, 78230 POC: Tracy Banks, tracy.e.banks2.civ@health.mil POC: Kirk Heyen, kirk.e.heyen.ctr@health.mil

What to check before bidding

  • Located in United States.
  • Source notice 832e20c89c0b4f549a4550a833b16cef on SAM.gov.
  • Notice published 5 Feb 2026; Tenqual indexed it 7 Feb 2026.
  • Deadline listed as 2 Apr 2026.
  • 5 tender documents identified.
  • Create a free tender alert to catch similar opportunities before the deadline pressure starts.